He explains the combo joins a GLP-1 receptor agonist with an amylin receptor agonist, following up on points he made a week earlier.
Recap by typeshit. Post by @drnadolsky on Instagram.
Endpoints News
Endpoints reports Eli Lilly is building a case for its triple agonist beyond obesity, where a launch is expected next year, with sleep apnea next in line.
Observational data link GLP-1 drugs to fewer cases of some cancers, but trials have yet to show they prevent cancer or help survival after a diagnosis.
BusinessWorld Online covers a Lilly weight loss drug still in clinical trials. Few details were given beyond the headline.
A short social post says drugs like Ozempic may lower heart attack and stroke risk, possibly beyond what weight loss alone explains.
HealthcareAIGuy says the two drugs earned about four times the AI labs' combined revenue, while only around 2% of people with obesity worldwide take them.
Researchers used AI to identify fungal peptides that taste salty or boost saltiness, aimed at cutting sodium in food. A food science find rather than a drug story.
Loading…